Stock events for DiaMedica Therapeutics, Inc. (DMAC)
DiaMedica Therapeutics' stock has experienced several positive movements, including a 53.20% increase over the past year as of October 22, 2025. The stock increased by 26% in the week leading up to August 19, 2025, and saw a "golden cross" in September 2025, supported by a positive earnings outlook. Shares rose 86.86% over the past quarter and 60.23% over the last year as of September 17, 2025, outperforming the S&P 500, with a 15.47% increase over one week and 20.8% over one month as of September 17, 2025.
Demand Seasonality affecting DiaMedica Therapeutics, Inc.’s stock price
Information regarding the demand seasonality for DiaMedica Therapeutics, Inc.'s products and services is not available in the provided search results.
Overview of DiaMedica Therapeutics, Inc.’s business
DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases, operating within the Healthcare sector. Its primary product candidate is DM199, designed to enhance the body's natural healing processes and restore proper blood flow, particularly in patients with ischemic stroke.
DMAC’s Geographic footprint
DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota, and primarily operates in the United States and Canada.
DMAC Corporate Image Assessment
DiaMedica Therapeutics has maintained a generally positive brand reputation among analysts, with a consensus rating of "Moderate Buy" based on ratings from four Wall Street analysts. The average price target is $12.33, suggesting a potential upside of approximately 79.3% from its current price. MarketBeat's evaluation scored DiaMedica Therapeutics higher than 34% of companies in the medical sector.
Ownership
DiaMedica Therapeutics Inc. has a diverse ownership structure, with individual insiders holding the largest share at 41%. Institutional shareholders account for 16.96% of the company, while retail investors hold 13.19%. Major institutional owners include Cooperman Leon G, Vanguard Group Inc, and BlackRock, Inc. Key individual/insider owners include Jan Stahlberg, owning 28.11% of the company, Thomas von Koch, holding 26.87%, and Richard Jacinto Ii, with 9.59% ownership.
Ask Our Expert AI Analyst
Price Chart
$7.06
